Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis

Guermazi A, Roemer F, Kompel A, Diaz L, Crema M, Brown M, Hickman A, Pixton G, Viktrup L, Fountaine R, Burr A, Sherlock S, West C (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Frank Roemer Institute of Radiology

Involved external institutions

Pfizer, Inc. US United States (USA) (US) Boston University US United States (USA) (US) Veterans Affairs Healthcare System Boston and Harvard Medical School US United States (USA) (US) Eli Lilly and Company US United States (USA) (US)

How to cite

APA:

Guermazi, A., Roemer, F., Kompel, A., Diaz, L., Crema, M., Brown, M.,... West, C. (2020). Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

Guermazi, Ali, et al. "Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2020.

BibTeX: Download